MS Clinical Trials in New York

43 active trials · 24 recruiting

43 active multiple sclerosis clinical trials have at least one study site in New York, 24 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 25 MS treatment centers in New York; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in New York

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 · Fludarabine

14 states120 participantsDetails ›

RecruitingPhase 1

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Sponsor: AstraZeneca

AZD0120 - Regimen 1 · AZD0120 - Regimen 2

8 states24 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

RecruitingPhase 2

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

Sponsor: State University of New York at Buffalo

metformin · Placebo

1 state30 participantsDetails ›

RecruitingNA

Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?

Sponsor: Universiteit Leiden

Conscientiousness Coaching Before Cog… · Sham Intervention Before Cognitive Re…

1 state126 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

RecruitingNA

A Study of the MIND Diet for Persons With Multiple Sclerosis

Sponsor: Icahn School of Medicine at Mount Sinai

Mediterranean-DASH Intervention for N… · Small Group

1 state100 participantsDetails ›

RecruitingNA

A Palliative Care Model Impact on Knowledge and Attitudes

Sponsor: Hunter College of City University of New York

Palliative care video comprises the c… · Palliative care written material

1 state50 participantsDetails ›

RecruitingPhase 1

Vancomycin Study in Multiple Sclerosis (MS)

Sponsor: Icahn School of Medicine at Mount Sinai

Vancomycin · Placebo

1 state12 participantsDetails ›

RecruitingNA

Noninvasive Vagal Nerve Stimulation

Sponsor: NYU Langone Health

Remotely Supervised Transcranial Dire… · Remotely Supervised Transcutaneous Au…

1 state30 participantsDetails ›

RecruitingPhase 2

Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)

Sponsor: NYU Langone Health

Active tDCS · Sham tDCS

1 state170 participantsDetails ›

Recruiting

Genes and Environment in Multiple Sclerosis

Sponsor: Columbia University

4 states5000 participantsDetails ›

Recruiting

NYSCF Scientific Discovery Biobank

Sponsor: New York Stem Cell Foundation Research Institute

Biological Sample Collection

1 state10000 participantsDetails ›

RecruitingNA

Task Specific Training for Advanced Multiple Sclerosis

Sponsor: Hunter College of City University of New York

Task specific physical therapy

1 state15 participantsDetails ›

Recruiting

Eccentric Exercise and Fatigue in Multiple Sclerosis

Sponsor: Hunter College of City University of New York

Resistance training

1 state30 participantsDetails ›

RecruitingNA

Effectiveness of Task Specific Home Exercise Program

Sponsor: New York Presbyterian Brooklyn Methodist Hospital

Task Specific Physical Therapy Home P…

1 state30 participantsDetails ›

Recruiting

Effect of Cooling on Balance Performance in Multiple Sclerosis

Sponsor: Hunter College of City University of New York

20 minutes of biking on a stationary …

1 state30 participantsDetails ›

By invitation onlyPhase 1

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Sponsor: Truway Health, Inc.

Low-Frequency Electromagnetic Resonan… · Sham Resonance Device (Inactive Control)

1 state120 participantsDetails ›

By invitation only

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

Sponsor: Icahn School of Medicine at Mount Sinai

1 state170 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Sponsor: TG Therapeutics, Inc.

Ublituximab

14 states1100 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patients

Biobank For MS And Other Demyelinating Diseases

Sponsor: Accelerated Cure Project for Multiple Sclerosis

9 states3226 participantsDetails ›

Closed to new patientsPhase 4

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Sponsor: The Cleveland Clinic

Early Highly Effective Therapies Group · Escalation Therapies Group

8 states800 participantsDetails ›

Closed to new patients

Serum Neurofilament Light in Multiple Sclerosis

Sponsor: Dent Neuroscience Research Center

Serum Neurofilament Light

1 state42 participantsDetails ›

Closed to new patientsNA

Home Based Tele-exercise for People With Chronic Neurological Impairments

Sponsor: Burke Medical Research Institute

Seated exercise

1 state60 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in New York

MS trials in other states